Evidence map›Paper›PMID 29080083›Full record

ArticleMetabolic brain disease2018

Evaluation of metformin effects in the chronic phase of spontaneous seizures in pilocarpine model of temporal lobe epilepsy.

Soraya Mehrabi, Nima Sanadgol, Mahmood Barati, Ali Shahbazi, Gelareh Vahabzadeh, Mitra Barzroudi, Morteza Seifi, Mazaher Gholipourmalekabadi, Fereshteh Golab

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Metformin role in Parkinson's disease: a double-sword effect.Molecular and cellular biochemistry · 2024
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Soraya MehrabiCellular and Molecular Research Center, Iran University of Medical Science, Tehran, Iran.
Nima SanadgolDepartment of Biology, Faculty of Sciences, University of Zabol, Zabol, Iran.
Mahmood BaratiDepartment of Biotechnology, Faculty of Allied Medicine, Iran University of Medical Science, Tehran, Iran.
Ali ShahbaziFaculty of Advanced Technologies in Medicine, Department of Neuroscience, Iran University of Medical Sciences, Tehran, Iran.
Gelareh VahabzadehCellular and Molecular Research Center, Iran University of Medical Science, Tehran, Iran.
Mitra BarzroudiDepartment of Anatomy, Iran University of Medical Sciences, Tehran, Iran.
Morteza SeifiDepartment of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Mazaher GholipourmalekabadiDepartment of Tissue Engineering & Regenerative Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.
Fereshteh GolabCellular and Molecular Research Center, Iran University of Medical Science, Tehran, Iran. fgolab520@gmail.com.
Iran University of Medical Sciences · IRUniversity of Alberta · CAZabol University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Temporal lobe epilepsy (TLE) is a common form of drug-resistant epilepsy that sometimes responds to dietary manipulation such as the 'ketogenic diet'. Here we have investigated the effects of metformin in the rat pilocaroin model of TLE. Male rats were treated with intra peritoneal injection of pilocarpine hydrochloride, in dose of 360 mg/kg to induce status epilepticus (SE). At 45 day after induction of SE, metformin was injected intraperitoneally in dose of 250 mg/kg/day for 5 days. We show that metformin potently reduces the progression of seizures and blocks seizure-induced over-expression of brain-derived neurotropic factor (BDNF) and its receptor, Tropomyosin receptor kinase B (TrkB). We have shown that this reduced expression pattern is mediated by the transcriptional co-repressor CtBP (C-terminal binding protein). Moreover, metformin decreased mechanistic target of rapamycin (mTOR) activation through activation of AMP-activated protein kinase (AMPK) signaling pathway. Our findings have been shown that metformin has anticonvulsant and antiepileptic properties, and suggesting that antiglycolytic compounds such as metformin may represent a new class of drugs for treating epilepsy.

Indexed as

AnimalsAnticonvulsantsDisease Models, AnimalEpilepsy, Temporal LobeMaleMetforminPilocarpineRats, WistarSeizuresAnticonvulsantsMetforminPilocarpineMetforminPilocarpineSpontaneous seizuresTemporal lobe epilepsy

Identifiers

PMID29080083
OpenAlexW2766048876

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.